<DOC>
	<DOCNO>NCT02304770</DOCNO>
	<brief_summary>The study examine effect aminolaevulinic acid ( ALA ) photodynamic therapy ( PDT ) cervical precancerous lesion woman .</brief_summary>
	<brief_title>Aminolaevulinic Acid Photodynamic Therapy Cervical Persistent HPV Infection Cervical Neoplasia</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
	<mesh_term>Aminolevulinic Acid</mesh_term>
	<criteria>1 . Premenopausal woman , 2550 year age 2 . Meet one 3 follow condition : highrisk HPVDNA persistently positive least 6 month , without CIN high grade lesion verify cervical biopsy within last 3 month ; CIN1 verify cervical biopsy within last 3 month highrisk HPVDNA positive ; CIN2/3 verify cervical biopsy within last 3 month , intense desire retain cervical structure function 3 . Satisfactory colposcopy examination ( visibility entire transformation zone entire lesion margin ) endocervical curettage negative 4 . In good health condition confirm past medical history , physical examination , electrocardiogram , laboratory test urinalysis screen baseline evaluation within last 4 week onset study 5 . Meet following condition : pregnancy test negative ; pregnancy plan trial ; sexuality reliable contraceptive measure take since last menstruation onset study , agree adopt reliable contraceptive measure study 6 . Written inform consent sign 1 . Atypical glandular cell undetermined significance ( AGUS ) adenocarcinoma situ ( AIS ) cytology , malignant cell cytology histology , suspicion either microinvasive invasive disease 2 . Invasive carcinoma possibility positive endocervical curettage colposcopy 3 . Severe pelvic inflammatory disease , severe cervicitis , severe gynaecological infection per clinical examination 4 . Undiagnosed vaginal bleeding 5 . With allergic disease present ; know suspected porphyria ; know allergy ALA similar compound 6 . Evidence history clinically significant cardiovascular , endocrine , neurologic , pulmonary , hematological , immunological , psychiatric , metabolic disease serious diseases 7 . Pregnancy nurse 8 . Therapeutic drug therapeutic measure apply cervix rectum within last 2 week onset study 9 . Participation clinical study within last 30 day 10 . Subjects investigator judge suitable participate study besides</criteria>
	<gender>Female</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>